Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat for HIV Latency Reversal
NCT01319383Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Feb 2011
- Primary completion
- Mar 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of North Carolina at Chapel Hill. Started Feb 2011; status: completed.
02
Drugs
vorinostat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01319383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01319383.